
Adrian Rawcliffe, Adaptimmune
Send us Fan Mail This episode features Adrian (Ad) Rawcliffe, CEO, Adaptimmune, recipient of the Life Sciences PA 2024 Patient Impact Award. Ad shares the story behind TECELRA - the first FDA approved engineered cell therapy for a solid tumor. Learn about the journey leading up to this groundbreaking approval, the challenges of bringing a cell therapy to market and the next steps for Adaptimmune in the landscape of tumor treatments.
Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.
